About HUS

From the nation’s leading law firm representing victims of HUS and other foodborne illness outbreaks.

Chapter 7

References

  1. Kunzendorf U, Karch H, Werber D, Haller H. (2011). Recent outbreak of hemolytic uremic syndrome in Germany. Kid Int. 80(9):900-2.
  2. Joseph A, et al. (2020). Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins. 12(2):67.
  3. Karmali MA. (2009). Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kid Int. 75(Supp. 112):S4-S7.
  4. Tarr PI, Gordon CA, Chandler WL. (2005). Shiga-toxin-producing Escherichia coli and hemolytic uraemic syndrome. Lancet. 365(9464):1073-86.
  5. Croxen A, et al. (2013). Recent Advances in Understanding Enteric Pathogenic Escherichia Coli. Clin Microbiol Rev. 26(4):822-80.
  6. Andreoli SP, Zimmerhackl LB. Hemolytic uremic syndrome. In: Geary DF, Shaefer F, eds. Comprehensive Pediatric Nephrology 1st ed, Philadelphia, PA: Mosby, Elsevier; 2008.
  7. Kemper MJ. (2012). Outbreak of hemolytic uremic syndrome caused by E. Coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol. 27(2):161-4.
  8. Liu Y, et al. (2011). Shiga Toxin Type 2 (Stx2), a Potential Agent of Bioterrorism, Has a Short Distribution and a Long Elimination Half-Life, and Induces Kidney and Thymus Lesions in Rats. Arch Toxicol. 85(9):1133-40.
  9. Qin J, et al. (2011). Identification of the Shiga Toxin-Producing Escherichia coli O104:H4 Strain Responsible for a Food Poisoning Outbreak in Germany by PCR. J Clin Microbiol. 49(9):3439-40.
  10. Bell BP, et al. (1997). Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics. 100(1):E12.
  11. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. (2000). The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 342(26):1930-6.
  12. Safdar N, Said A, Gangnon RE, Maki GD. (2002). Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA. 288(8):996-1001.
  13. Amerling R, Ronco C, Winchester J. (2012). Continuous Flow Peritoneal Dialysis: Update 2012. Contrib Nephrol. 178:205-15.
  14. Walsh PR, Sally J. (2019). Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol. 34(9):1485-92.
  15. Menne J, et al. (2012). Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ. 345:e4565.
  16. Kielstein JT, et al. (2012). Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant. 27(10):3807-15.
  17. Sheoran AS, et al. (2005). Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun. 73(8):4607-13.
  18. Khalid M, Andreoli S. (2018). Extrarenal Manifestations of the Hemolytic Uremic Syndrome Associated With Shiga Toxin-Producing Escherichia Coli (STEC HUS). Pediatr Nephrol. 34(12):2495-507.
  19. Goldstein SL. (2012). Acute Kidney Injury in Children and Its Potential Consequences in Adulthood. Blood Purif. 33(1-3):131‐7.
  20. Siegler RL, Pavia AT, Cook JB. (1997). Hemolytic-uremic Syndrome in Adolescents. Arch Pediatr Adolesc Med. 151(2):165‐9.
  21. Siegler RL, et al. (1991). Long-term Outcome and Prognostic Indicators in the Hemolytic-Uremic Syndrome. J Pediatr. 118(2):195‐200.
  22. Tremblay JM, et al. (2013). A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun. 81(12):4592-603.
  23. Agbas A, et al. (2018). Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab. Pediatr Nephrol. 33(12):2371-81.
  24. Weil BR, Andreoli SP, Billmire DF. (2010). Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome. Pediatr Nephrol. 25(9):1693-8.
  25. Andreoli SP, Bergstein JM. (1982). Development of insulin-dependent diabetes mellitus during the hemolytic-uremic syndrome. J Pediatr. 100(4):541-5.
  26. Burns JC, Berman ER, Fagre JL, Shikes RH, Lum GM. (1982). Pancreatic islet cell necrosis: association with hemolytic-uremic syndrome. J Pediatr. 100(4):582-4.
  27. Andreoli S, Bergstein J. (1987). Exocrine and endocrine pancreatic insufficiency and calcinosis after hemolytic uremic syndrome. J Pediatr. 110(5):816-7.
  28. Nesmith JD, Ellis E. (2007). Childhood hemolytic uremic syndrome is associated with adolescent-onset diabetes mellitus. Pediatr Nephrol. 22(2):294-7.
  29. Schlieper A, et al. (1999). Neuropsychological sequelae of haemolytic uraemic syndrome. Arch Dis Child. 80(3):214-20.
  30. Qamar IU, et al. (1996). Long-term neurological sequelae of hemolytic-uremic syndrome: a preliminary report. Pediatr Nephrol. 10(4):504-6.
  31. Bauer A, et al. (2014). Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome. Pediatr Nephrol. 29(9):1607-15.
  32. Oakes RS, Kirkham JK, Nelson RD, Siegler RL. (2008). Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol. 23(8):1303-8.
  33. Gagnadoux MF, et al. (1996). Long-term (15-25 Years) Outcome of Childhood Hemolytic-Uremic Syndrome. Clin Nephrol. 46(1):39-41.
  34. Calletti MG, Gallo G, Gianantonio CA. (1996). Development of Focal Segmental Sclerosis and Hyalinosis in Hemolytic Uremic Syndrome. Pediatr Nephrol. 10(6):687-92.
  35. Fitzpatrick R. (1991). Surveys of patients satisfaction: I-- Important general considerations. BMJ. 302(6781):887-9.
  36. Tonshoff B, et al. (1994). Outcome and prognostic determinants in the hemolytic uremic syndrome of children. Nephron. 68:63–70.
  37. Calderon-Margalit R. (2018). History of Childhood Kidney Disease and Risk of Adult End-Stage Renal Disease. N Engl J Med. 378:428-38.
  38. Ingelfinger JR. (2018). A Disturbing Legacy of Childhood Kidney Disease. N Engl J Med. 378:470-1.
  39. Martin-Navarro JA, et al. (2013). Long-term renal prognosis of typical haemolytic-uremic syndrome suffered in infancy. Nefrologia. 33(3):433-5. 
  40. Vaterodt L, et al. (2018). Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood. Frontiers in Pediatrics. 6:220.
  41. Mammen C, et al. (2012). Long-term Risk of CKD in Children Surviving Episodes of Acute Kidney Injury in the Intensive Care Unit: A Prospective Cohort Study. Am J Kidney Dis. 59(4):523-30.
  42. Heung M, Chawla LS. (2012). Predicting Progression to Chronic Kidney Disease After Recovery From Acute Kidney Injury. Curr Opin Nephrol Hypertens. 21(6):628-34.
  43. Monet-Didailler C, et al. (2019). Long-term Outcome of Diarrhea-Associated Hemolytic Uremic Syndrome Is Poorly Related to Markers of Kidney Injury at 1-year Follow-Up in a Population-Based Cohort. Pediatr Nephrol. 34(4):657-62.
  44. Small G, Watson AR, Evans JH, Gallagher J. (1999). Hemolytic Uremic Syndrome: Defining the Need for Long-Term Follow-Up. Clin Nephrol. 52(6):352-6.
  45. Kunzendorf U, Karch H, Werber D, Haller H. (2011). Recent outbreak of hemolytic uremic syndrome in Germany. Kid Int. 80(9):900-2.
  46. Joseph A, et al. (2020). Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins. 12(2):67.
  47. Karmali MA. (2009). Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kid Int. 75(Supp. 112):S4-S7.
  48. Tarr PI, Gordon CA, Chandler WL. (2005). Shiga-toxin-producing Escherichia coli and hemolytic uraemic syndrome. Lancet. 365(9464):1073-86.
  49. Croxen A, et al. (2013). Recent Advances in Understanding Enteric Pathogenic Escherichia Coli. Clin Microbiol Rev. 26(4):822-80.
  50. Andreoli SP, Zimmerhackl LB. Hemolytic uremic syndrome. In: Geary DF, Shaefer F, eds. Comprehensive Pediatric Nephrology 1st ed, Philadelphia, PA: Mosby, Elsevier; 2008.
  51. Kemper MJ. (2012). Outbreak of hemolytic uremic syndrome caused by E. Coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol. 27(2):161-4.
  52. Liu Y, et al. (2011). Shiga Toxin Type 2 (Stx2), a Potential Agent of Bioterrorism, Has a Short Distribution and a Long Elimination Half-Life, and Induces Kidney and Thymus Lesions in Rats. Arch Toxicol. 85(9):1133-40.
  53. Qin J, et al. (2011). Identification of the Shiga Toxin-Producing Escherichia coli O104:H4 Strain Responsible for a Food Poisoning Outbreak in Germany by PCR. J Clin Microbiol. 49(9):3439-40.
  54. Bell BP, et al. (1997). Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics. 100(1):E12.
  55. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. (2000). The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 342(26):1930-6.

Previous Chapter

HUS Research

Next Chapter

Symptoms of HUS

Related Blog Articles

The E. coli blog supplements this Marler Clark website About HUS | Subscribe

Connect with Marler Clark

Office:

1012 First Avenue
Fifth Floor
Seattle, WA 98104

Hours:

M-F, 8:30 am - 5:00 pm, Pacific

Call toll free:

1 (800) 884-9840

If you have questions about foodborne illness, your rights or the legal process, we’d be happy to answer them for you.